Table 3.
Unified response rates of advanced thymic carcinoma patients treated with cisplatin-based or carboplatin-based chemotherapy regimens
| Regimen | Author, year | Study design | Stage | No. of patients | Responders | RR | PFS (mos) | MST (mos) |
|---|---|---|---|---|---|---|---|---|
| Cisplatin-based chemotherapy | ||||||||
| ADOC | Agatsuma et al. (2011) | S | IVa/IVb | 34 | 17 | 50 % | N/A | 21.3 |
| CODE | Yoh et al. (2003) | S | III/IVa/IVb | 12 | 5 | 42 % | 5.6 | 46 |
| VIP | Grassin et al. (2011) | S | III/IVa/IVb | 8 | 2 | 25 % | – | – |
| CDDP/DTXa | Park et al. (2013) | G | III/IVa | 18 | 12 | 66.7 % | – | – |
| CDDP/CPT-11 | Present study | S | IVa/IVb/rec | 12 | 9 | 75.0 % | 7.4 | 52.4 |
| Total | 84 | 45 | 53.6 % | |||||
| Carboplatin-based chemotherapy | ||||||||
| CarboPTX | Lemma et al. (2011) | G | III/IVa/IVb | 23 | 5 | 21.7 % | 5.0 | 20.0 |
| CarboPTX | Igawa et al. (2010) | S | IVa/IVb | 11 | 4 | 36 % | 7.9 | 22.7 |
| CarboPTX | Takeda et al. (2013) | G | III/IVa/IVb | 39 | 14 | 35.9 % | 7.52 | Not reached |
| CarboPTX | Furugen et al. (2011) | S | IVa/IVb/rec | 16 | 6 | 37.5 % | 8.6 | 49.4 |
| CarboAMRa | Kawashima et al. (2013) | G | Invasivea | 33 | 11 | 30 % | 7.6 | 27.3 |
| Total | 122 | 40 | 32.8 % | |||||
G prospective multicenter group phase II trial, S single-center experience, RR response rate, PFS progression-free survival, OS overall survival, ADOC adriamycin, cisplatin, vincristine and cyclophosphamide, CODE adriamycin, cisplatin, vincristine and etoposide, CarboAMR carboplatin and amrubicin, CarboPTX carboplatin and paclitaxel, CDDP/CPT-11 cisplatin and irinotecan, CDDP/DTX cisplatin/docetaxel
aThe subset for thymic carcinoma